TC |
Stat |
Stk |
Ins |
Fil |
+d |
+w |
+m |
+q |
+h |
+y |
avg |
|---|
Filing Date |
T Date |
Ticker |
Issuer | Inc | Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
6/2/20 21:30 | 5/29/20 | ADAP | Adaptimmune Therapeutics Plc | X0 | Health | BioPrd | Biological Products, (No Diag | Noble James | X0 | D | S | -4,666 | 9.33 | 0 | -500 | -100 | 0 | D | |||||||||||||||
1/15/20 20:01 | 1/13/20 | ADAP | Adaptimmune Therapeutics Plc | X0 | Health | BioPrd | Biological Products, (No Diag | Noble James | X0 | D | S | -1,400 | 4.67 | 0 | -300 | -100 | 0 | D | |||||||||||||||
5/29/19 20:00 | 5/24/19 | GWPH | Gw Pharmaceuticals Plc | Health | Drug | Pharmaceutical Preparations | Noble James | X0 | D | M.d | 331 | 4.01 | 0 | 83 | 28 | D | |||||||||||||||||
5/29/19 20:00 | 5/24/19 | GWPH | Gw Pharmaceuticals Plc | Health | Drug | Pharmaceutical Preparations | Noble James | X0 | D | S.d | -1,265 | 15.32 | 0 | -83 | -75 | 28 | D | ||||||||||||||||
5/17/19 18:00 | 5/16/19 | ADAP | Adaptimmune Therapeutics Plc | X0 | Health | BioPrd | Biological Products, (No Diag | Noble James | X0 | DO | CEO | M | 254 | 0.1430 | 0 | 1,773 | 14 | 14,719 | D | ||||||||||||||
5/9/07 09:28 | 5/8/07 | CRGN | Curagen Corp | DE | Health | Biolab | Commercial Physical & Biologi | Noble James | CT | D | P | 57 | 2.87 | 0 | 20 | New | 20 | D |
| D | Derivative transaction in filing (usually option exercise) |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| A | Amended filing |
| E | Error detected in filing |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |